• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.

作者信息

Benzecry V, Pravettoni V, Segatto G, Marzano A V, Ferrucci S

机构信息

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.

UOC Dermatologia, Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.

DOI:10.18176/jiaci.0614
PMID:32732182
Abstract
摘要

相似文献

1
Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.2型炎症：度普利尤单抗成功治疗特应性皮炎、哮喘和高嗜酸性粒细胞增多症。
J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.
2
Mechanisms of Dupilumab.度普利尤单抗的作用机制。
Clin Exp Allergy. 2020 Jan;50(1):5-14. doi: 10.1111/cea.13491. Epub 2019 Sep 30.
3
Dupilumab for the treatment of adolescents with atopic dermatitis.度普利尤单抗治疗青少年特应性皮炎。
Expert Rev Clin Immunol. 2020 Jul;16(7):641-650. doi: 10.1080/1744666X.2020.1801420. Epub 2020 Aug 13.
4
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?2017 年批准用于治疗特应性皮炎后dupilumab 的新进展：有哪些新进展和下一步计划？
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.
5
Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.度普利尤单抗治疗特应性皮炎的聚焦：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2017 May 15;11:1473-1480. doi: 10.2147/DDDT.S113192. eCollection 2017.
6
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.使用度普利尤单抗治疗的重度特应性皮炎患者的体重增加：一项队列研究。
BMC Dermatol. 2020 Sep 22;20(1):8. doi: 10.1186/s12895-020-00103-0.
7
Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant.度普利尤单抗治疗携带显性负性CARD11变异的重度特应性皮炎的疗效。
Clin Exp Dermatol. 2021 Oct;46(7):1334-1335. doi: 10.1111/ced.14686. Epub 2021 Jun 2.
8
Dupilumab: Mechanism of action, clinical, and translational science.度普利尤单抗：作用机制、临床和转化科学。
Clin Transl Sci. 2024 Aug;17(8):e13899. doi: 10.1111/cts.13899.
9
No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.在意大利伦巴第大区贝加莫这个高疫情地区，接受度普利尤单抗治疗特应性皮炎的患者中，没有证据表明其感染2019冠状病毒病（COVID-19）的风险增加。
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e433-e434. doi: 10.1111/jdv.16552. Epub 2020 Jun 15.
10
Drug evaluation review: dupilumab in atopic dermatitis.药物评估综述：度普利尤单抗治疗特应性皮炎
Immunotherapy. 2015;7(10):1043-58. doi: 10.2217/imt.15.69.

引用本文的文献

1
The role of ILC2s in asthma combined with atopic dermatitis: bridging the gap from research to clinical practice.2型固有淋巴细胞在哮喘合并特应性皮炎中的作用：弥合从研究到临床实践的差距
Front Immunol. 2025 Apr 1;16:1567817. doi: 10.3389/fimmu.2025.1567817. eCollection 2025.
2
Dupilumab Use in Patients With Hypereosinophilic Syndromes: A Multicenter Case Series and Review of the Literature.度普利尤单抗在高嗜酸性粒细胞综合征患者中的应用：一项多中心病例系列研究及文献综述
J Allergy Clin Immunol Pract. 2025 Jan;13(1):167-175.e6. doi: 10.1016/j.jaip.2024.10.036. Epub 2024 Nov 6.
3
Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis.
生物制剂对哮喘控制不佳患者的比较疗效：一项网状荟萃分析。
World Allergy Organ J. 2024 Jul 18;17(7):100934. doi: 10.1016/j.waojou.2024.100934. eCollection 2024 Jul.
4
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.胸腺基质淋巴细胞生成素和特泽普单抗在气道疾病中的作用：从生理作用到靶向治疗。
Int J Mol Sci. 2024 May 29;25(11):5972. doi: 10.3390/ijms25115972.
5
Which Factors Are Associated with Persistence of Depressive and Anxiety Symptoms in Patients Affected by Atopic Dermatitis despite 2-Year Treatment with Dupilumab?尽管使用度普利尤单抗治疗了两年，但哪些因素与特应性皮炎患者抑郁和焦虑症状的持续存在有关？
J Clin Med. 2024 Mar 29;13(7):1980. doi: 10.3390/jcm13071980.
6
Asthma improvement in patients treated with dupilumab for severe atopic dermatitis.使用度普利尤单抗治疗重度特应性皮炎患者时哮喘症状的改善情况。
Front Allergy. 2023 Sep 11;4:1223657. doi: 10.3389/falgy.2023.1223657. eCollection 2023.
7
Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome.度普利尤单抗作为一种新型的用于嗜酸性粒细胞增多综合征的类固醇节省疗法。
JAAD Case Rep. 2022 Mar 17;29:106-109. doi: 10.1016/j.jdcr.2022.03.017. eCollection 2022 Nov.
8
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.使用度普利尤单抗（一种白细胞介素4和13双重受体拮抗剂）对重度哮喘进行生物治疗
Vaccines (Basel). 2022 Jun 19;10(6):974. doi: 10.3390/vaccines10060974.
9
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets.哮喘中的白细胞介素4和13：关键的病理生理细胞因子和可成药分子靶点
Front Pharmacol. 2022 Mar 8;13:851940. doi: 10.3389/fphar.2022.851940. eCollection 2022.
10
Study of Hypersensitivity to in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients?头颈部型特应性皮炎患者对[具体物质]超敏反应的研究：它能否作为这些患者的生物标志物和治疗指标？ （注：原文中“in Patients with Atopic Dermatitis with Head and Neck Pattern”里的“in”后面应该有具体物质，这里按照完整的翻译思路给出译文，需根据实际原文补充完整该物质）
Life (Basel). 2022 Feb 16;12(2):299. doi: 10.3390/life12020299.